Tag: funding

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

SHREWSBURY, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, an AI-native decentralized infrastructure platform, today announced the start of its Final Bonus Phase, following the successful completion of all 15 presale stages and the achievement of a major milestone—$21.1 million raised from a global community of early contributors. This final round offers a fixed price of $0.007125 per LCAI token, providing one last opportunity for participants ahead of the mainnet launch scheduled for July 2025.

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.

SHREWSBURY, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the AI-native blockchain infrastructure platform, has entered its Bonus Round after successfully completing 15 presale stages and raising more than $21.1 million from early supporters. The Bonus Round is now live at a fixed token price of $0.007125, marking the final opportunity for contributors to access Lightchain AI tokens before the mainnet launch scheduled for July 2025.

$22.7 million second loan advance follows the first $68.3 million received in December 2024

Today 1 July 2025, Fitch announced a one notch downgrade of Statkraft AS following weakening performance and financial metrics. The long-term issuer default rating and senior unsecured rating were lowered from A- to BBB+ with a stable outlook.

The rating change aligns with the company’s long-standing rating targets. Statkraft has consistently maintained a target of an A- rating from S&P and a BBB+ from Fitch. Statkraft remains committed to maintaining these targets.

On 18 June, Statkraft announced an updated strategy, strengthening core activities and competitiveness: 
https://www.statkraft.com/newsroom/news-and-stories/2025/statkraft-strengthens-core-activities-and-competitiveness-following-strategic-review/